{
    "clinical_study": {
        "@rank": "36645", 
        "arm_group": [
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal Placebo (0 mcg)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "BA058 (Abaloparatide) Transdermal Microneedle Patch 0 mcg daily"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal (50 mcg)", 
                "arm_group_type": "Experimental", 
                "description": "BA058 (Abaloparatide)Transdermal Microneedle Patch - 50 mcg daily"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal (100 mcg)", 
                "arm_group_type": "Experimental", 
                "description": "BA058 (Abaloparatide) Transdermal Microneedle Patch - 100 mcg daily"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal (150 mcg)", 
                "arm_group_type": "Experimental", 
                "description": "BA058 (Abaloparatide) Transdermal Microneedle Patch - 150 mcg daily"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Injection (80 mcg)", 
                "arm_group_type": "Active Comparator", 
                "description": "BA058 (Abaloparatide-SC) Subcutaneous Injection - 80 mcg daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy\n      postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD)\n      and serum markers of bone metabolism when compared to Transdermal Placebo and BA058\n      Injection for 6 months of treatment."
        }, 
        "brief_title": "Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Post Menopausal Osteoporosis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoporosis", 
                "Osteoporosis, Postmenopausal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal woman, less than 85 years old.\n\n          -  BMD T-score \u2264 -2.5 of spine or hip (femoral neck) or \u2264 -2.0 with previous fracture\n             (within 5 years).\n\n          -  Normal physical exam, vital signs, electrocardiogram (ECG) and medical history.\n\n          -  Laboratory tests within the normal range including serum calcium, Vit D, PTH(1-84),\n             serum phosphorus and alkaline phosphatase.\n\n        Exclusion Criteria:\n\n          -  BMD T-score \u2264 -5.0 at the lumbar spine or hip.\n\n          -  History of bone disorders (e.g., Paget's disease) other than postmenopausal\n             osteoporosis.\n\n          -  Significantly impaired renal function.\n\n          -  History of any cancer."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674621", 
            "org_study_id": "BA058-05-007", 
            "secondary_id": "2012-001921-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal Placebo (0 mcg)", 
                "description": "BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months", 
                "intervention_name": "BA058 Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Abaloparatide Placebo"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal (50 mcg)", 
                "description": "BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months", 
                "intervention_name": "BA058 Transdermal (50 mcg)", 
                "intervention_type": "Drug", 
                "other_name": "Abaloparatide Transdermal (50 mcg)"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal (100 mcg)", 
                "description": "BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months", 
                "intervention_name": "BA058 Transdermal (100 mcg)", 
                "intervention_type": "Drug", 
                "other_name": "Abaloparatide Transdermal (100 mcg)"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Transdermal (150 mcg)", 
                "description": "BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months", 
                "intervention_name": "BA058 Transdermal (150 mcg)", 
                "intervention_type": "Drug", 
                "other_name": "Abaloparatide Transdermal (150 mcg)"
            }, 
            {
                "arm_group_label": "BA058 (Abaloparatide) Injection (80 mcg)", 
                "description": "BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months", 
                "intervention_name": "BA058 Injection (80 mcg)", 
                "intervention_type": "Drug", 
                "other_name": "Abaloparatide Injection (80 mcg)"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "BA058", 
            "Abaloparatide", 
            "Osteo", 
            "Osteoporosis", 
            "Transdermal", 
            "Patch"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ballerup", 
                        "country": "Denmark"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vejie", 
                        "country": "Denmark"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallinn", 
                        "country": "Estonia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Denmark", 
                "Estonia", 
                "Hong Kong", 
                "Poland"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 (Abaloparatide) Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal (Abaloparatide Transdermal)) in Healthy Postmenopausal Women With Osteoporosis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Hong Kong: Department of Health", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Medicines Agency", 
                "Estonia: The State Agency of Medicine", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Poland: Ministry of Health", 
                "Romania: National Medicines Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in BMD, using DXA results; active compared to placebo.", 
            "measure": "BMD (Lumbar Spine)", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in BMD, using DXA results; active compared to placebo.", 
                "measure": "BMD (Hip and Forearm)", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "description": "Change in laboratory results; active compared to placebo.", 
                "measure": "Serum markers of bone formation and resorption", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Physical examinations, vital signs, electrocardiograms, clinical laboratory tests, local tolerance, and adverse events.", 
                "measure": "Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }
        ], 
        "source": "Radius Health, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Nordic Bioscience A/S", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Radius Health, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}